Dr. Philip Gold, MD
Claim this profileSwedish Cancer Institute
Studies Colorectal Cancer
Studies Solid Tumors
6 reported clinical trials
29 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
dMMR negative
MSI-H positive
2Solid Tumors
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Philip Gold, MD is currently running
Botensilimab + Chemotherapy
for Pancreatic Cancer
This trial is testing whether adding a new drug, botensilimab, to standard chemotherapy can better treat patients with advanced pancreatic cancer. The study will ensure the new drug is safe and determine the right dose. It will also compare the effectiveness of the new combination treatment to chemotherapy alone.
Recruiting1 award Phase 2
Targeted Therapy
for Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Recruiting1 award Phase 29 criteria
More about Philip Gold, MD
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Philip Gold, MD has experience with
- Botensilimab
- Pembrolizumab
- Balstilimab
- Standard Of Care
- Cetuximab
- Evorpacept (ALX148)
Breakdown of trials Philip Gold, MD has run
Colorectal Cancer
Pancreatic Cancer
Multiple Myeloma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Philip Gold, MD specialize in?
Philip Gold, MD focuses on Colorectal Cancer and Solid Tumors. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are dMMR negative.
Is Philip Gold, MD currently recruiting for clinical trials?
Yes, Philip Gold, MD is currently recruiting for 2 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Philip Gold, MD has studied deeply?
Yes, Philip Gold, MD has studied treatments such as Botensilimab, Pembrolizumab, Balstilimab.
What is the best way to schedule an appointment with Philip Gold, MD?
Apply for one of the trials that Philip Gold, MD is conducting.
What is the office address of Philip Gold, MD?
The office of Philip Gold, MD is located at: Swedish Cancer Institute, Seattle, Washington 98104 United States. This is the address for their practice at the Swedish Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.